Jessica Vetere
Physician Assistant · Houston, TXNPI 1316725609
Payments from drug & device makers
Across 134 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$707
- Amgen$427
- Pfizer$182
- Lilly USA, LLC$177
- AbbVie$164
- plus $620 from 15 others
What the payments were for
- Food & beverage$3,359100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $1,081 |
| AstraZeneca | 22 | $707 |
| Amgen | 22 | $427 |
| Pfizer | 7 | $182 |
| Lilly USA, LLC | 9 | $177 |
| AbbVie | 3 | $164 |
| Bayer | 6 | $113 |
| Dexcom, Inc. | 5 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $80 |
| Corcept Therapeutics | 3 | $64 |
| Inspire Medical Systems, Inc. | 2 | $43 |
| Merck | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Tempus AI, Inc | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Inari Medical, Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Cequr Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,359 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 17 | $32,730 |
| FarxigaDapagliflozin Propanediol | 17 | $26,630 |
| MounjaroTirzepatide | 14 | $15,338 |
| JardianceEmpagliflozin | 11 | $13,427 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,610 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $2,124 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,351 |
| Epinephrine | 11 | $1,277 |
| Levothyroxine Sodium | 70 | $1,076 |
| Atorvastatin Calcium | 85 | $680 |
| Fluoxetine Hcl | 13 | $516 |
| Triamcinolone Acetonide | 25 | $383 |
| Losartan Potassium | 43 | $346 |
| Tamsulosin Hcl | 29 | $315 |
| Ezetimibe | 19 | $280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,081 | $32,73017 claims |
| AstraZenecaFarxiga | $707 | $26,63017 claims |
| Lilly USA, LLCMounjaro | $177 | $15,33814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Houston
- Simone SteeleHouston$237K
- Amanda WilhiteHouston$207K
- Christina YazdaniHouston$72K
- Julie Huynh-LuHouston$64K
- Jennifer FalconeHouston$48K
- Jacqueline WeatherlyHouston$47K
- Samantha SalvatoraHouston$45K
- Virginia SchneiderHouston$43K
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.